BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 27276388)

  • 1. Is There a Role for PET/CT Parameters to Characterize Benign, Malignant, and Metastatic Parotid Tumors?
    Kendi AT; Magliocca KR; Corey A; Galt JR; Switchenko J; Wadsworth JT; El-Deiry MW; Schuster DM; Saba NF; Hudgins PA
    AJR Am J Roentgenol; 2016 Sep; 207(3):635-40. PubMed ID: 27276388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of metabolic heterogeneity as a reliable parameter for differentiating malignant parotid gland tumors.
    Kim BS; Kim SJ; Pak K
    Ann Nucl Med; 2016 Jun; 30(5):346-54. PubMed ID: 26897010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parotid gland tumors: preliminary data for the value of FDG PET/CT diagnostic parameters.
    Hadiprodjo D; Ryan T; Truong MT; Mercier G; Subramaniam RM
    AJR Am J Roentgenol; 2012 Feb; 198(2):W185-90. PubMed ID: 22268210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total lesion glycolysis as the best 18F-FDG PET/CT parameter in differentiating intermediate-high risk adrenal incidentaloma.
    Kim YI; Cheon GJ; Paeng JC; Cho JY; Kang KW; Chung JK; Kim EE; Lee DS
    Nucl Med Commun; 2014 Jun; 35(6):606-12. PubMed ID: 24598843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG-PET/CT parameters as imaging biomarkers in oral cavity squamous cell carcinoma, is visual analysis of PET and contrast enhanced CT better than the numbers?
    Kendi AT; Corey A; Magliocca KR; Nickleach DC; Galt J; Switchenko JM; El-Deiry MW; Wadsworth JT; Hudgins PA; Saba NF; Schuster DM
    Eur J Radiol; 2015 Jun; 84(6):1171-6. PubMed ID: 25816993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
    Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
    Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a role for PET/CT parameters to differentiate thyroid cartilage invasion from penetration?
    Kendi AT; Corey A; Magliocca KR; Galt JR; Zhang C; Chen Z; Higgins K; Beitler JJ; Wadsworth JT; El-Deiry MW; Schuster DM; Saba NF; Hudgins PA
    Eur J Radiol; 2016 Feb; 85(2):319-23. PubMed ID: 26781136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of conventional whole-body ¹⁸F-FDG PET/CT in the incidental findings of parotid masses.
    Wang HC; Zuo CT; Hua FC; Huang ZM; Tan HB; Zhao J; Guan YH
    Ann Nucl Med; 2010 Oct; 24(8):571-7. PubMed ID: 20640540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Optimal Quantification of FDG PET Imaging in the Clinical Practice of Radiology.
    Ziai P; Hayeri MR; Salei A; Salavati A; Houshmand S; Alavi A; Teytelboym OM
    Radiographics; 2016; 36(2):481-96. PubMed ID: 26963458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of Metabolic Tumor Volume and Total Lesion Glycolysis Measured Using ¹⁸F-FDG PET/CT in Locally Advanced and Metastatic Gallbladder Carcinoma.
    Chun YJ; Jeung HC; Park HS; Park JS; Rha SY; Choi HJ; Lee JH; Jeon TJ
    Yonsei Med J; 2019 Jul; 60(7):604-610. PubMed ID: 31250573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Volume-metabolic Combined Parameters from (18)F-FDG PET/CT May Help Predict the Outcomes of Cervical Carcinoma.
    Sun Y; Lu P; Yu L
    Acad Radiol; 2016 May; 23(5):605-10. PubMed ID: 26853968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intra-parotid lymph node metastasis in patients with non-cutaneous head and neck cancers: clinical and imaging features for differentiation from simultaneous parotid primary tumor.
    Kim HJ; Yoon DY; Hong JH; Yun EJ; Baek S; Kim ES; Park MW; Kwon KH
    Acta Radiol; 2020 Dec; 61(12):1628-1635. PubMed ID: 32138522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorine-18 fluorodeoxyglucose positron emission tomography imaging of parotid mass lesions.
    Okamura T; Kawabe J; Koyama K; Ochi H; Yamada R; Sakamoto H; Matsuda M; Ohashi Y; Nakai Y
    Acta Otolaryngol Suppl; 1998; 538():209-13. PubMed ID: 9879423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do 18F-FDG PET/CT parameters in oropharyngeal and oral cavity squamous cell carcinomas indicate HPV status?
    Kendi AT; Magliocca K; Corey A; Nickleach DC; Galt J; Higgins K; Beitler JJ; El-Deiry MW; Wadsworth JT; Hudgins PA; Saba NF; Schuster DM
    Clin Nucl Med; 2015 Mar; 40(3):e196-200. PubMed ID: 25608156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
    Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S
    Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients.
    Husby JA; Reitan BC; Biermann M; Trovik J; Bjørge L; Magnussen IJ; Salvesen ØO; Salvesen HB; Haldorsen IS
    J Nucl Med; 2015 Aug; 56(8):1191-8. PubMed ID: 26045311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma.
    Lim R; Eaton A; Lee NY; Setton J; Ohri N; Rao S; Wong R; Fury M; Schöder H
    J Nucl Med; 2012 Oct; 53(10):1506-13. PubMed ID: 22895812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis.
    Son SH; Lee SW; Jeong SY; Song BI; Chae YS; Ahn BC; Lee J
    AJR Am J Roentgenol; 2015 Oct; 205(4):878-85. PubMed ID: 26204115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.